Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, the recent approval of the radiolabeled somatostatin analog <sup>177</sup>Lu-DOTATATE has had a significant impact on management of neuroendocrine malignancies.
|
30737297 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Most human pancreatic adenocarcinoma cells do not express somatostatin receptors and somatostatin does not inhibit the growth of these cancers.
|
12069503 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways.
|
19148511 |
2009 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
|
30904441 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The truncated somatostatin receptor sst5TMD4 is associated with poor prognosis in breast cancer and increases breast cancer cell malignancy.
|
27507050 |
2016 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We investigated somatostatin receptors (SSTRs) in surgical specimens of prostate cancer and benign prostate hyperplasia (BPH), a normal immortalized epithelial cell line (PNT1), epithelial cancer cell lines, and stromal cells in short-term culture derived from normal and BPH biopsies.
|
8674827 |
1995 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We aimed to assess (1) the accuracy of somatostatin receptor scintigraphy, (2) histological features with focus on malignancy and genotype-phenotype correlations, and (3) prognosis of VHL-EPT.
|
18580449 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatostatin may play an important role in the regulation of cancer growth including pancreatic cancer by interaction with somatostatin receptors (SSTRs) on the cell surface.
|
15706439 |
2005 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results suggest that SS analogues may be useful for diagnostic localization and treatment of biliary tract malignancies.
|
7768398 |
1995 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatostatin (SST) and its five receptors (sst1-5 encoded by SSTR1-5 genes) comprise a pleiotropic system present in most endocrine-related cancers, some of which are successfully treated with SST analogs.
|
28905400 |
2017 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Neuroendocrine tumors (NETs) have proven to be appropriate neoplasms for peptide receptor radionuclide therapy (PRRT), as the majority of these slow-growing malignancies overexpress somatostatin receptors.
|
28864881 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
However, circulating CgA concentrations exhibit considerable intra-individual biological variation, are altered by proton pump inhibitors (PPIs) and somatostatin analogues and are elevated in non-NEN malignancies.
|
23939195 |
2014 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Octreotide (OCT) is a synthetic somatostatin analog that induces apoptosis in different cancer cell lines in vitro.
|
25925002 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells.
|
21927030 |
2012 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The treatment landscape of well-differentiated neuroendocrine tumors (NETs) has considerably expanded in recent years, and both somatostatin analogs, radiolabeled somatostatin analogs, everolimus, and sunitinib have been incorporated within the therapeutic armamentarium against these malignancies.
|
31346813 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, somatostatin analogs are a promising class of compounds for diagnosis and treatment of cancer.
|
7912834 |
1993 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatostatin analogs and radiopeptides in cancer therapy.
|
12385036 |
2002 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The presence of these SST receptor subtypes in human ovarian cancers allows the use of SST analogs and their radionuclide and cytotoxic derivatives for the diagnosis and treatment of this malignancy.
|
11061491 |
2000 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In case of normal aging SST mRNA expression did not alter, but decreased in cancer (p < 0.05).
|
25723531 |
2015 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
An overexpression of somatostatin (SST) as well as chemokine CXCR4 and endothelin A (ETA) receptors has been shown for many types of cancer.
|
29696364 |
2018 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Gastrointestinal peptide hormone receptors, like somatostatin receptors, are often overexpressed in human cancer, allowing receptor-targeted tumor imaging and therapy.
|
18223557 |
2008 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here, we characterized a long-term culture (SST-secreting cancer (SS-C cells)) established from a human somatostatinoma.
|
16601281 |
2006 |
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
The aim of the present study was to assess the standardized incidence ratios (SIRs) of different types of cancer in acromegaly on a large series of acromegalic patients managed in the somatostatin analogs era.
|
28710115 |
2017 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The review will focus on how BB, NTS, VIP, and SST receptors can facilitate the early detection and treatment of cancer.
|
30008698 |
2018 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Alterations in somatostatin (SST)/cortistatin (CORT) and ghrelin systems have been associated to development/progression of various endocrine-related cancers, wherein they may become useful diagnostic, prognostic and therapeutic biomarkers.
|
28577942 |
2017 |